Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.58 |
| ▸ | PPID | Q08752 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839616 | 1.00 | CTSL (0.59) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL838492 | 1.00 | CTSL (0.59) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL11318126 | 0.88 | CTSL (0.51) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL25496208 | 0.88 | TAS1R3 (0.61) | CTSKCTSSTAS1R3TAS1R1PPID | |
| SCHEMBL10407750 | 0.88 | TAS1R3 (0.68) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL6241209 | 0.88 | TAS1R3 (0.68) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL6648068 | 0.87 | CYP26A1 (0.50) | CTSLCTSKCTSBCTSSTAS1R3 | |
| SCHEMBL29188972 | 0.86 | CYP26A1 (0.54) | CTSLTDP1CYP26A1 | |
| SCHEMBL810660 | 0.86 | TAS1R3 (0.68) | TAS1R3TAS1R1PPIDPOLBL3MBTL1 | |
| SCHEMBL28814272 | 0.86 | TAS1R3 (0.60) | CTSLCTSKCTSBCTSSTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8772336-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | AXYS PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| CN-101248184-B | Process for production of optically active (S or R)-a-amino acid or optically active (S or R)-a -amino acid ester | UBE INDUSTRIES | 2013-01-16 | — | — | CN | disclosed |
| US-8318748-B2 | Cathepsin cysteine protease inhibitors | Merck, Sharp & Dohme Corp. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8143052-B2 | Process for preparing optically active (S or R)-α amino acid and (R or S)-α amino acid ester in one phase organic reaction medium | UBE INDUSTRIES, LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090042260-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE (S OR R)-ALPHA-AMINO ACID AND OPTICALLY ACTIVE (R OR S)-ALPHA-AMINO ACID ESTER | UBE INDUSTRIES, LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| CN-101248184-A | Process for production of optically active (S or R)-a-amino acid or optically active (S or R)-a -amino acid ester | UBE INDUSTRIES (JP) | 2008-08-20 | — | — | CN | disclosed |
| EP-1942193-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE (S OR R)-a-AMINO ACID OR OPTICALLY ACTIVE (S OR R)-a -AMINO ACID ESTER | Ube Industries, Ltd. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | CTSB, CTSS, CTSZ | CTSL 8/4885CTSK 4/4885CTSB 1/4885 |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSL 8/4885CTSK 4/4885CTSB 1/4885 |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSL 8/4885CTSK 4/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.